Sort
48,018 grants matching “immunotherapy”
Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer
$670,826Stephen B Gruber · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies
$670,820David R Boulware · University Of Minnesota · R01 · FY2022 · AI
Costimulation blockade, chimerism and tolerance across varying degrees of MHC dis
$670,784Christian P Larsen · Emory University · U19 · FY2010 · AI
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
$670,756Timothy A Marlowe · Faknostics, Llc · R42 · FY2022 · CA
DNA DAMAGE AS A PREDICTIVE BIOMARKER FOR IMMUNOTHERAPY RESPONSE IN OVARIAN CANCER
$670,729University Of Alabama At Birmingham · · FY2021 · Department of the Army
FAST-FNA immune cell profiling in HNSCC
$670,725Ralph Weissleder · Massachusetts General Hospital · R01 · FY2025 · CA
FAST-FNA immune cell profiling in HNSCC
$670,725Ralph Weissleder · Massachusetts General Hospital · R01 · FY2021 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression
$670,711James R. Heath · Institute For Systems Biology · U01 · FY2021 · CA
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study
$670,697Joshua Aiden Hill · Fred Hutchinson Cancer Research Center · U01 · FY2020 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression
$670,576James R. Heath · Institute For Systems Biology · U01 · FY2020 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1
$670,441Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2024 · CA
T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade
$670,428Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2021 · CA
Project 3: Integrative approach tounderstanding the mechanism ofcostimulation
$670,406Arlene H Sharpe · Yale University · P01 · FY2019 · AI
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
$670,358Tina Cascone · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
$670,358Tina Cascone · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Further Development of Multi-Antigen Vaccines for Primary and Secondary Prevention of Bladder Cancer HHSN2612015000361 TO: HHSN26100011 PP: 9/17/2018 to 3/16/2020
$670,206Clinton Grubbs · University Of Alabama At Birmingham · N01 · FY2018 · CA
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
$670,182Anna Karolina Palucka · Jackson Laboratory · R01 · FY2020 · CA
Project 1: Transgenic TCR-mediated tumor therapy
$669,971Philip D Greenberg · University Of Washington · P01 · FY2020 · CA
Strategies to Enhance Lymphoid Recovery After Radiation-Induced Injury
$669,953Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2011 · AI
Resistance mechanisms to autophagy-modulating therapies
$669,910Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2022 · CA
Imaging Acidosis and Immune Therapy in PDAC
$669,832Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Imaging Acidosis and Immune Therapy in PDAC
$669,832Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Project 3: Integrative approach tounderstanding the mechanism ofcostimulation
$669,787Arlene H Sharpe · Yale University · P01 · FY2020 · AI
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy
$669,635Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Improved Treatment of American Cutaneous Leishmaniasis by Immunomodulation
$669,610Diane McMahon Pratt · Yale University · R01 · FY2014 · AI